Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 14/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.36 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.36 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30090827 | 1.00 | ACVR1 (0.41) | ACVR1FGFR3KCNH2HRH3HRH4 | |
| SCHEMBL28805725 | 0.90 | L3MBTL3 (0.46) | KCNH2HRH3 | |
| SCHEMBL27767958 | 0.90 | HRH3 (0.42) | HRH3 | |
| SCHEMBL27901888 | 0.89 | L3MBTL3 (0.44) | KCNH2HRH3 | |
| SCHEMBL27919685 | 0.89 | L3MBTL3 (0.44) | KCNH2HRH3 | |
| SCHEMBL467882 | 0.88 | HRH4 (0.48) | HRH3HRH4FLT3 | |
| SCHEMBL28997652 | 0.84 | HRH3 (0.42) | HRH3 | |
| SCHEMBL27768006 | 0.79 | NOS3 (0.39) | ACVR1HRH3 | |
| SCHEMBL467949 | 0.79 | EML4 (0.42) | ACVR1FGFR3PDGFRBPDGFRAFLT3 | |
| SCHEMBL28784755 | 0.79 | ACVR1 (0.33) | ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101622246-B | Polycyclic heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-30 | — | — | CN | claimed |
| CN-101622248-B | N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2013-04-17 | — | — | CN | claimed |
| CN-101622246-A | Polycyclic heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2010-01-06 | — | — | CN | claimed |
| CN-101622248-A | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2010-01-06 | — | — | CN | claimed |
| CN-116075303-A | Method of selecting patients treated with a combination of an AXL inhibitor and an immune checkpoint modulator | 卑尔根生物股份公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115916344-A | AXL inhibitors for antiviral therapy | 卑尔根生物股份公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-101622246-B | Polycyclic heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-30 | — | — | CN | disclosed |
| CN-101622248-B | N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2013-04-17 | — | — | CN | disclosed |
| EP-2387395-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8040491-B2 | Exposure method, substrate stage, exposure apparatus, and device manufacturing method | NIKON CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| CN-101622246-A | Polycyclic heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2010-01-06 | — | — | CN | disclosed |
| CN-101622248-A | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2010-01-06 | — | — | CN | disclosed |